Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04592653
Title A Study of ALKS 4230 on the Tumor Microenvironment (ARTISTRY-3)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Alkermes, Inc.
Indications

triple-receptor negative breast cancer

ovarian cancer

Advanced Solid Tumor

skin melanoma

colorectal cancer

renal cell carcinoma

Therapies

ALKS 4230 + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Alkermes Investigator Site Recruiting Grand Rapids Michigan 49546 United States Details
MD Anderson Cancer Center Recruiting Houston Texas 77030 United States Details
Alkermes Investigator Site Recruiting West Valley City Utah 84119 United States Details
Alkermes Investigator Site Recruiting Fairfax Virginia 22031 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field